Skip to main content
Humacyte, Inc. logo

Humacyte, Inc. — Investor Relations & Filings

Ticker · HUMA ISIN · US0207512023 US Manufacturing
Filings indexed 457 across all filing types
Latest filing 2025-11-17 Director's Dealing
Country US United States of America
Listing US HUMA

About Humacyte, Inc.

https://humacyte.com/

Humacyte, Inc. is a regenerative medicine company that develops and manufactures universally implantable, bioengineered human tissues. The company utilizes a proprietary platform to produce acellular tissues that are designed to be available "off-the-shelf." Upon implantation, these tissues are repopulated by the patient's own cells, remodeling over time to become living tissue. Its first U.S. FDA-approved product, SYMVESS™, is a human acellular vessel (HAV) developed for arterial replacement and repair, particularly in cases of vascular trauma. Humacyte is leveraging its foundational technology to build a pipeline of product candidates for a broad range of diseases, injuries, and chronic conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-11-17 English
FORM 4
Director's Dealing
2025-11-17 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-12 English
FORM 8-K
Regulatory Filings
2025-11-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-16 English
FORM 8-K
Regulatory Filings
2025-10-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.